TELESIS BIO News

Telesis Bio Announces 1-For-18 Reverse Stock Split, Will Open For Trading On The Nasdaq Global Select Market On May 9, 2024 On A Post-Split Basis

Telesis Bio Inc. (the Company) (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synth

Benzinga04:29

Press Release: Telesis Bio Announces Reverse Stock Split

Telesis Bio Announces Reverse Stock Split SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers t

Dow Jones04:05

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. The company's market cap stands at $212.3 million. Fresh2 Group (NASDAQ:FRES) stock rose 10

BenzingaApr 26 04:32

Telesis Bio Leadership Shake-Up and Board Expansion

TipRanksApr 18 21:13

Telesis Bio Inc. Announces Strategic Focus on Game-changing Gibson SOLA Enzymatic DNA Synthesis (EDS) Platform and BioXp MRNA Solutions and Announces New Leadership

SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the com

GlobeNewswireApr 18 21:00

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersClene (NASDAQ:CLNN) shares moved upwards by 54.9% to $0.48 during Tuesday's after-market session. The company's market cap stands at $61.6 million. Talphera (NASDAQ:TLPH) shares moved upwards b

BenzingaApr 17 04:31

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ

BenzingaApr 4 20:09

Telesis Bio Q4 EPS $(0.61) Misses $(0.22) Estimate, Sales $6.98M Miss $7.00M Estimate

Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.22) by 177.27 percent. This is a 117.86 percent decrease over losses of $(0.

BenzingaMar 29 04:33

Earnings Flash (TBIO) TELESIS BIO Reports Q4 Revenue $7M

04:06 PM EDT, 03/28/2024 (MT Newswires) -- Earnings Flash (TBIO) TELESIS BIO Reports Q4 Revenue $7M

MT NewswiresMar 29 04:06

Telesis Bio 4Q Loss $17.7M >TBIO

Telesis Bio 4Q Loss $17.7M >TBIO

Dow JonesMar 29 04:05

Press Release: Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enab

Dow JonesMar 29 04:05

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersSCWorx (NASDAQ:WORX) stock increased by 60.8% to $2.75 during Wednesday's after-market session. The market value of their outstanding shares is at $3.3 million. IO Biotech (NASDAQ:IOBT) stock i

BenzingaMar 7 05:31

12 Health Care Stocks Moving In Tuesday's Intraday Session

GainersJanux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutics (NASDAQ:VKTX) shares

BenzingaFeb 28 01:31

Analysts Offer Insights on Healthcare Companies: Telesis Bio (TBIO) and Springworks Therapeutics (SWTX)

TipRanksFeb 27 23:20

Telesis Bio Announces 26.3% Drop in Prelim Q4 Revenue

Seeking AlphaFeb 26 22:31

Telesis Bio Reports Record Q4 BioXp Kit Sales, Margin Growth

InvestingFeb 26 22:30

Telesis Bio Sees Prelim. 2023 Total Consolidated Revenue Of $27.5M, Up From $27.4M YoY; Sees FY24 Total Revenue $7M, Down From $9.5M YoY

Total consolidated revenue for the 2023 fiscal year is expected to be $27.5 million, up slightly from $27.4 million achieved in 2022.Total revenue for the fourth quarter of 2023 is expected to be $7.0

BenzingaFeb 26 22:17

Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results

Globe NewswireFeb 26 22:15

Telesis Bio (TBIO) Surge: Unraveling the Mystery Behind the Meteoric Rise

In an unexpected turn of events, Telesis Bio, Inc. (NASDAQ: TBIO) witnessed an extraordinary surge in its stock price, sending shockwaves through the market. The company's shares soared by an unprecedented 99% during after-hours trading, following a remarkable 30% climb in the regular session. This surge, accompanied by an astonishing volume of 17 million shares ...

Stocks TelegraphFeb 23 15:41

Telesis Bio Granted EUR Patent #3503915 For "Genetically Engineered Vibrio Natriegens (Host Organism For Cloning And Manipulating DNA)".

Telesis Bio Granted EUR Patent #3503915 For "Genetically Engineered Vibrio Natriegens (Host Organism For Cloning And Manipulating DNA)".

BenzingaFeb 23 04:57